Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Positive benefit-risk balance continues for glitazones – EMEA

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      European Medicines Agency (EMEA).European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Media Release: 18 Oct 2007. Available from: URL: http://www.emea.europa.eu

    2. 2.

      GlaxoSmirthKline.European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment. Media Release: 18 Oct 2007. Available from: URL: http://www.gsk.com

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Positive benefit-risk balance continues for glitazones – EMEA. React. Wkly. 1175, 2 (2007). https://doi.org/10.2165/00128415-200711750-00003

    Download citation

    Keywords

    • Rosiglitazone
    • Pioglitazone
    • Bone Fracture
    • Product Characteristic
    • Ischaemic Heart Disease